Picture: Zelluna

Jens-Peter Marschner joins Zelluna

Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.

Jens-Peter Marschner is a medical doctor with a focus on biological compounds in oncology and immuno-oncology development. Prior to joining Zelluna, Jens-Peter was the Medical Lead Oncology for Western Europe and Canada at Abbvie. Previously, as CMO for Affimed, he was responsible for clinical strategy and development of its bi-specific antibodies. He significantly supported Affimed’s transition from a technical platform company to a clinical development company. He has also been a clinical team leader for Merck KGaA, contributing significantly to the successful launch of cetuximab, and was VP in different medical and clinical leadership positions including immuno-oncology. Jens-Peter has also held senior roles at Bayer and Boehringer Mannheim.